Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Starna Therapeutics Closes $40M Series B+ Round to Advance In Vivo CAR-T and Extrahepatic mRNA Delivery Platforms

Fineline Cube May 11, 2026
Company Deals

CureGene Pharmaceutical Secures RMB 300 Million Series C to Advance Global Clinical Pipeline

Fineline Cube May 9, 2026
Company Deals

Hengrui Pharmaceuticals Expands Greater Bay Area Presence with Hong Kong Office Launch and Cancer Foundation Partnership

Fineline Cube May 9, 2026
Company Deals

Fosun Pharma Secures Exclusive China Rights to InxMed’s FAK Inhibitors for Solid Tumor Treatment

Fineline Cube May 9, 2026
Company Deals

Harbour BioMed Joins $165M Cross Financing Round for Windward Bio to Advance Ultra-Long-Acting TSLP Immunotherapies

Fineline Cube May 8, 2026
Policy / Regulatory

NHSA Launches 2026 NRDL Adjustment with Expanded Eligibility Criteria and Revised Weight Standards

Fineline Cube May 11, 2026
Company Drug

Henlius Biotech Expands European Footprint with Two Additional EC Approvals for HanSiZhuang PD-1 Inhibitor

Fineline Cube May 11, 2026
Company Drug

Henlius Biotech Receives FDA Clearance for Phase I Trial of HLX05-N Cetuximab Biosimilar in Metastatic Colorectal Cancer

Fineline Cube May 11, 2026
Company

Amgen Announces $900M Investment to Expand Ohio Manufacturing

Fineline Cube Apr 27, 2025

US biotech leader Amgen (NASDAQ: AMGN) announced a USD 900 million investment to expand its...

Company Drug

Johnson & Johnson’s Tremfya Approved by EC for Ulcerative Colitis Treatment

Fineline Cube Apr 27, 2025

US giant Johnson & Johnson (J&J; NYSE: JNJ) announced that it has received regulatory approval...

Company Drug

Keymed Biosciences Gains NMPA Approval for Phase I/II Study of CM518D1

Fineline Cube Apr 27, 2025

China-based Keymed Biosciences Inc. (HKG: 2162) announced that it has received approval from the National...

Company Drug

Akeso’s Ivonescimab Approved by NMPA for First-Line PD-L1-Positive NSCLC

Fineline Cube Apr 27, 2025

China-based Akeso, Inc. (HKG: 9926) announced that its supplementary New Drug Application (sNDA) for ivonescimab,...

Company Drug

Hefei Lifeon Gains NMPA Approval for Nexletol Clinical Trials in China

Fineline Cube Apr 26, 2025

China-based Hefei Lifeon Pharmaceutical Co., Ltd (SHE: 003020) announced that it has received clinical trial...

Company Drug

Fujian Cosunter Gains NMPA Clearance for Phase II HBV Study of GST-HG131 and GST-HG141

Fineline Cube Apr 26, 2025

China-based Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436) announced that it has received clearance from...

Company Drug

Anhui Anke’s Allogeneic CAR-T Therapy UTAA09 Approved for r/r B-ALL Trials

Fineline Cube Apr 25, 2025

China-based Anhui Anke Biotechnology (Group) Co., Ltd (SHE: 300009) announced that its joint venture with...

Company Drug

Juventas Cell Therapy’s CNCT 19 Gains NMPA Approval for Refractory Lupus Nephritis

Fineline Cube Apr 25, 2025

China-based Juventas Cell Therapy Ltd announced that its chimeric antigen receptor (CAR)-T cell therapy, inaticabtagene...

Company Drug

TYK Medicines Submits Pre-NDA Package for Asandeutertinib in NSCLC Brain Metastasis

Fineline Cube Apr 25, 2025

China-based TYK Medicines, Inc. (HKG: 2410) announced the formal submission of a pre-NDA communication package...

Company Medical Device

MicroPort Scientific’s MRI-Conditional ALIZEA Hybrid Pacing System Secures CE Certification

Fineline Cube Apr 25, 2025

Shanghai-based medical device giant MicroPort Scientific Corp. (HKG: 0853), through its French subsidiary MicroPort Cardiac...

Company Drug

AbbVie Files BLA for TrenibotE in Moderate to Severe Glabellar Lines Treatment

Fineline Cube Apr 25, 2025

US-based AbbVie (NYSE: ABBV) announced that it has filed a Biologics License Application (BLA) with...

Company Drug

GenFleet’s KRAS G12D Inhibitor GFH375/VS-7375 Gains FDA Trial Approval

Fineline Cube Apr 25, 2025

Shanghai-based biotech GenFleet Therapeutics announced that its GFH375/VS-7375, an oral KRAS G12D inhibitor co-developed with...

Company Deals Drug

Innate Pharma and Sanofi Restructure 2016 Research Agreement on CD123 ANKET Drug

Fineline Cube Apr 25, 2025

France-based Innate Pharma SA has announced a significant adjustment to its 2016 research and licensing...

Company Medical Device

Medtronic Submits 510(k) Applications for Interoperable Diabetes Management System

Fineline Cube Apr 25, 2025

US-Irish firm Medtronic plc (NYSE: MDT) has submitted twin 510(k) applications to the U.S. Food...

Company Medical Device

Thermo Fisher Announces $2 Billion US Investment to Strengthen Life Sciences Infrastructure

Fineline Cube Apr 25, 2025

US-based life sciences giant Thermo Fisher Scientific Inc. (NYSE: TMO) has announced a USD 2...

Company Deals

Merck KGaA Nears Completion of $3.5 Billion Acquisition of SpringWorks Therapeutics

Fineline Cube Apr 25, 2025

German pharmaceutical major Merck KGaA (ETR: MRK) is reportedly nearing the completion of its acquisition of...

Company Deals

CN Bio and Pharmaron Partner to Validate and Expand OOC Technology Applications

Fineline Cube Apr 25, 2025

CN Bio, a UK-based provider of Organ-on-a-chip (OOC) systems and solutions, has entered into a...

Company

Gan & Lee Pharmaceuticals Reports 417 Million USD Revenue and 80.75% Profit Surge in 2024

Fineline Cube Apr 25, 2025

Gan & Lee Pharmaceuticals (SHA: 603087) reported revenues of RMB 3.045 billion (USD 417 million)...

Company Drug

Hepalink Secures SAHPRA Approval for Ivenoxin in South Africa

Fineline Cube Apr 25, 2025

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (SHE: 002399, HKG: 9989) has announced that it has...

Company Drug

Akeso’s Penpulimab Gains FDA Approval for Nasopharyngeal Carcinoma Treatment

Fineline Cube Apr 25, 2025

China-based Akeso, Inc. (HKG: 9926) announced that it has received marketing approval from the US...

Posts pagination

1 … 168 169 170 … 663

Recent updates

  • Starna Therapeutics Closes $40M Series B+ Round to Advance In Vivo CAR-T and Extrahepatic mRNA Delivery Platforms
  • Henlius Biotech Expands European Footprint with Two Additional EC Approvals for HanSiZhuang PD-1 Inhibitor
  • Henlius Biotech Receives FDA Clearance for Phase I Trial of HLX05-N Cetuximab Biosimilar in Metastatic Colorectal Cancer
  • MicroPort CardioFlow Secures CE Mark for ENO Series Pacemakers with Advanced LBBAP Capability
  • Hansoh Pharmaceutical’s B7-H3 ADC HS-20093 Receives Fifth NMPA Breakthrough Therapy Designation for Esophageal Cancer
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Starna Therapeutics Closes $40M Series B+ Round to Advance In Vivo CAR-T and Extrahepatic mRNA Delivery Platforms

Company Drug

Henlius Biotech Expands European Footprint with Two Additional EC Approvals for HanSiZhuang PD-1 Inhibitor

Company Drug

Henlius Biotech Receives FDA Clearance for Phase I Trial of HLX05-N Cetuximab Biosimilar in Metastatic Colorectal Cancer

Medical Device

MicroPort CardioFlow Secures CE Mark for ENO Series Pacemakers with Advanced LBBAP Capability

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.